Gene Bridges Licenses Recombineering Technology to Chugai Pharmaceutical Co., Ltd.
“Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese Pharmaceutical company, which found the existing license agreement worthwhile expanding.”
Gene Bridges is represented in Japan by the distribution partner Funakoshi.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.